综述

靶向人表皮生长因子受体3单克隆抗体抗肿瘤的研究进展

  • 杨炳能 陈哲文
展开
  • 上海生物制品研究所有限责任公司第一研究室  200051; 上海生物制品研究所有限责任公司质量保证部  201403

网络出版日期: 2025-08-16

Advances in studies on cancer treatment by anti-human epidermal growth factor receptor 3 monoclonal antibody

Expand
  • No. 1 Research Laboratory, Shanghai Institute of Biological Products Co., Ltd., Shanghai 200051, China; Department of Quality Assurance, Shanghai Institute of Biological Products Co., Ltd., Shanghai 201403, China

Online published: 2025-08-16

摘要

人表皮生长因子受体(human epidermal growth factor receptor,HER/ ErbB)3是表皮生长因子受体家族成员之一。大量基础研究和临床试验表明,ErbB3在整个表皮生长因子受体信号传导通路以及肿瘤耐药性作用中发挥着至关重要的作用。此文综合近年来国内外对靶向ErbB3单克隆抗体(单抗)抗肿瘤的研究进展,对ErbB3参与肿瘤进程的机制、靶向ErbB3单抗对肿瘤的抑制作用,以及靶向ErbB3单抗抗肿瘤的作用机制进行综述。

本文引用格式

杨炳能 陈哲文 . 靶向人表皮生长因子受体3单克隆抗体抗肿瘤的研究进展[J]. 国际生物制品学杂志, 2019 , 42(6) : 289 -293 . DOI: 10.3760/cma.j.issn.1673-4211.2019.06.007

Abstract

Human epidermal growth factor receptor (HER/ ErbB)3 is a member of epidermal growth factor receptor (EGFR) family. Numerous basic researches and clinical trials have shown that ErbB3 plays a crucial role in the EGFR signaling pathway as well as tumor resistance. This article summarizes latest domestic and abroad literatures reporting the effect of anti-ErbB3 monoclonal antibody on various cancers, and reviews the recent research advances in the mechanism of ErbB3-involving cancer progression, the inhibitory effect of anti-ErbB3 monoclonal antibody on cancers and the anti-tumor mechanism of anti-ErbB3 monoclonal antibody.
文章导航

/